drugset
drugset / Trial / NCT04428086

A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.

NCT04428086 ↗

Phase 1 Completed 19 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib on Rosuvastatin or Metformin. The secondary objective of the study was to assess the safety of Apatinib alone or Rosuvastatin/Metformin alone or concomitant medication.

Timeline

Start
2020-07-27
Primary completion
2021-08-22
Completion
2021-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Rivoceranib Small molecule 250 mg —
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

cancer